Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 RoslinCT and Lykan Bioscience Combine to Create Cell Therapy CDMO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

RoslinCT and Lykan Bioscience Combine to Create Cell Therapy CDMO

Creates global leader in process development and GMP manufacturing of advanced cell and gene therapies with transatlantic footprint in the US and UK.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

RoslinCT, a cell and gene therapy contract development and manufacturing organization (CDMO) developing life-changing therapies in Edinburgh’s BioQuarter, and Lykan Bioscience, a CDMO focused on cell-based therapies, have entered into a business combination agreement to form a global advanced therapies CDMO.

The combined group will offer process development expertise and cGMP manufacturing for a broad range of autologous and allogeneic cell therapies, with expertise in gene editing and industry-leading induced pluripotent stem cell (iPSC) capabilities.

The group will benefit from significantly expanded capacity, with process and analytical development laboratories and cGMP manufacturing facilities in Edinburgh, Scotland, and in Hopkinton, MA. Lykan has a 64,000 sq. ft. state-of-the-art cell therapy manufacturing facility and innovation/development laboratories with 16 cGMP processing suites running by the end of 2022. Further laboratory and cGMP capacity expansion in Scotland is planned to build on RoslinCT’s existing 40,000 sq. ft facilities, including 8 cGMP suites.

With demand for high-quality development and manufacturing capacity increasing across the world, this complementary pairing of RoslinCT and Lykan will shorten development and manufacturing timelines for advanced therapy sponsors, facilitating clinical and commercial GMP product release on both sides of the Atlantic.

RoslinCT CEO Peter Coleman and Lykan president and CEO Patrick Lucy will remain in their current roles. Together, the new entity will have a global headcount of approximately 300 employees.

“This combination puts us in a strong position as a leading global CDMO in the process development and manufacturing of advanced cell therapies, and we look forward to working with our new colleagues at Lykan to fuel future growth and meet the increasing demand for innovative therapies,” said Coleman.

Lucy added, “We are delighted to combine with RoslinCT to better serve the growing demand for manufacturing capacity and expand the range of innovative services we can provide our partners to support the development of advanced cell and gene therapies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics